SVSilvia Velazquez-Garcia

Silvia Velazquez-Garcia

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Silvia Velazquez-Garcia has a total of 80 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Increased SGK1 activity potentiates mineralocorticoid/NaCl-induced hypertension and kidney injury

    by Catalina Sierra-Ramos, Silvia Velazquez-Garcia, Ayse Gokce Keskus, Arianna Vastola-Mascolo, Ana Elena Rodríguez-Rodríguez, Sergio Luis-Lima, Guadalberto Hernández, Juan F. Navarro-González, Esteban Porrini, Ozlen Konu, et al.

    The serum and glucocorticoid-induced kinase 1 (SGK1) stimulates aldosterone-dependent renal Na + reabsorption and modulates blood pressure. In addition, genetic ablation or pharmacological inhibition of SGK1 limits the development of kidney inflammation and fibrosis in response to excess mineralocorticoid signalling. In this work we tested the hypothesis that a systemic increase in SGK1 activity would potentiate mineralocorticoid/salt-induced hypertension and kidney injury. To that end, we used a transgenic mouse model with increased SGK1 activity. Mineralocorticoid/salt-induced hypertension and kidney damage was induced by unilateral nephrectomy and treatment with deoxycorticosterone acetate and NaCl in drinking water for six weeks. Our results demonstrate higher systolic blood pressure in treated transgenic mice when compared to wild type counterparts. Transgenic mice showed a mild increase in glomerular filtration rate, increased albuminuria, exacerbated glomerular hypertrophy and fibrosis. Transcriptomic analysis showed that extracellular matrix and immune response related terms were enriched in the downregulated and upregulated genes, respectively, in transgenic mice. In conclusion, we propose that systemically increased SGK1 activity is a risk factor for the development of mineralocorticoid-dependent hypertension and incipient kidney injury in the context of low renal mass.

  • SGK1 activation exacerbates diet-induced obesity, metabolic syndrome and hypertension

    by Catalina Sierra-Ramos, Silvia Velazquez-Garcia, Arianna Vastola-Mascolo, Guadalberto Hernández, Nourdine Faresse, Diego Alvarez de la Rosa

    The serum- and glucocorticoid-induced kinase 1 (SGK1) is a transcriptional target of steroid hormones including glucocorticoids or aldosterone in addition to other stimuli such as glucose. SGK1 is activated via phosphoinositide 3-kinase, placing it downstream of insulin signaling. SGK1 participates in the upregulation of kidney Na+ reabsorption by aldosterone and has been linked to obesity-related hypertension in humans. We hypothesized that a systemic increase in SGK1 activity may trigger a multiplicity of mechanisms leading to simultaneous development of the main conditions that characterize the metabolic syndrome (MetS), including hypertension. We used a transgenic mouse model made with a bacterial artificial chromosome containing the whole mouse Sgk1 gene modified to introduce an activating point mutation. Wild type or transgenic 14-week-old male mice were fed with standard chow diet or high-fat diet for up to 18 weeks. Development of the main features of MetS and hepatic steatosis were monitored, and in vitro adipocyte differentiation was studied. Our results show that transgenic animals under high-fat diet rapidly and markedly develop MetS characterized by obesity, glucose intolerance, insulin resistance, dyslipidemia and hypertension. In addition, SGK1 gain-of-function accelerates the development of hepatic steatosis. Our study suggests that inappropriate SGK1 activity represents a risk factor in developing MetS with hypertension and related end-organ damage. Our data support SGK1 as a possible therapeutic target in MetS and related complications and provides a useful gain-of-function model for pre-clinical drug testing.


  • Synthetic biology: insights into biological computation

    by Romilde Manzoni, Arturo Urrios, Silvia Velazquez-Garcia, Eulàlia de Nadal, Francesc Posas

    Synthetic biology attempts to rationally engineer biological systems in order to perform desired functions. Our increasing understanding of biological systems guides this rational design, while the huge background in electronics for building circuits defines the methodology.


  • Open Access

    Glucose homeostasis changes and pancreatic β-cell proliferation after switching to cyclosporin in tacrolimus-induced diabetes mellitus

    by Ana Elena Rodríguez-Rodríguez, Javier Triñanes, Esteban Porrini, Silvia Velázquez-García, Cecilia Fumero, María Jose Vega-Prieto, María Luisa Díez-Fuentes, Sergio Luis Lima, Eduardo Salido, Armando Torres


  • Open Access

    Cambios en la homeostasis de la glucosa y la proliferación de la célula beta pancreática tras el cambio a ciclosporina en la diabetes inducida por tacrolimus

    by Ana Elena Rodríguez-Rodríguez, Javier Triñanes, Esteban Porrini, Silvia Velázquez-García, Cecilia Fumero, María Jose Vega-Prieto, María Luisa Díez-Fuentes, Sergio Luis Lima, Eduardo Salido, Armando Torres


  • Open Access

    The Higher Diabetogenic Risk of Tacrolimus Depends on Pre-Existing Insulin Resistance. A Study in Obese and Lean Zucker Rats

    by A. E. Rodriguez‐Rodriguez, J. Triñanes, S. Velazquez-Garcia, E. Porrini, M. J. Vega Prieto, M. L. Diez Fuentes, M. Arevalo, E. Salido Ruiz, A. Torres


  • Connexin-dependent signaling in neuro-hormonal systems

    by Ilaria Potolicchio, Valentina Cigliola, Silvia Velazquez-Garcia, Philippe Klee, Amina Valjevac, Dina Kapic, Esad Cosovic, Orhan Lepara, Almira Hadzovic-Dzuvo, Zakira Mornjacovic, et al.


  • Open Access

    Activation of Protein Kinase C-ζ in Pancreatic β-Cells In Vivo Improves Glucose Tolerance and Induces β-Cell Expansion via mTOR Activation

    by Silvia Velazquez-Garcia, Shelley Valle, Taylor C. Rosa, Karen K. Takane, Cem Demirci, Juan C. Alvarez-Perez, Jose M. Mellado-Gil, Sara Ernst, Donald K. Scott, Rupangi C. Vasavada, et al.

    OBJECTIVE: PKC-ζ activation is a key signaling event for growth factor–induced β-cell replication in vitro. However, the effect of direct PKC-ζ activation in the β-cell in vivo is unknown. In this study, we examined the effects of PKC-ζ activation in β-cell expansion and function in vivo in mice and the mechanisms associated with these effects. RESEARCH DESIGN AND METHODS: We characterized glucose homeostasis and β-cell phenotype of transgenic (TG) mice with constitutive activation of PKC-ζ in the β-cell. We also analyzed the expression and regulation of signaling pathways, G1/S cell cycle molecules, and β-cell functional markers in TG and wild-type mouse islets. RESULTS: TG mice displayed increased plasma insulin, improved glucose tolerance, and enhanced insulin secretion with concomitant upregulation of islet insulin and glucokinase expression. In addition, TG mice displayed increased β-cell proliferation, size, and mass compared with wild-type littermates. The increase in β-cell proliferation was associated with upregulation of cyclins D1, D2, D3, and A and downregulation of p21. Phosphorylation of D-cyclins, known to initiate their rapid degradation, was reduced in TG mouse islets. Phosphorylation/inactivation of GSK-3β and phosphorylation/activation of mTOR, critical regulators of D-cyclin expression and β-cell proliferation, were enhanced in TG mouse islets, without changes in Akt phosphorylation status. Rapamycin treatment in vivo eliminated the increases in β-cell proliferation, size, and mass; the upregulation of cyclins Ds and A in TG mice; and the improvement in glucose tolerance—identifying mTOR as a novel downstream mediator of PKC-ζ–induced β-cell replication and expansion in vivo. CONCLUSIONS: PKC-ζ, through mTOR activation, modifies the expression pattern of β-cell cycle molecules leading to increased β-cell replication and mass with a concomitant enhancement in β-cell function. Approaches to enhance PKC-ζ activity may be of value as a therapeutic strategy for the treatment of diabetes.


  • Open Access

    Disruption of Hepatocyte Growth Factor/c-Met Signaling Enhances Pancreatic β-Cell Death and Accelerates the Onset of Diabetes

    by Jose Mellado-Gil, Taylor C. Rosa, Cem Demirci, Jose A. Gonzalez-Pertusa, Silvia Velazquez-Garcia, Sara Ernst, Shelley Valle, Rupangi C. Vasavada, Andrew F. Stewart, Laura C. Alonso, et al.

    OBJECTIVE: To determine the role of hepatocyte growth factor (HGF)/c-Met on β-cell survival in diabetogenic conditions in vivo and in response to cytokines in vitro. RESEARCH DESIGN AND METHODS: We generated pancreas-specific c-Met-null (PancMet KO) mice and characterized their response to diabetes induced by multiple low-dose streptozotocin (MLDS) administration. We also analyzed the effect of HGF/c-Met signaling in vitro on cytokine-induced β-cell death in mouse and human islets, specifically examining the role of nuclear factor (NF)-κB. RESULTS: Islets exposed in vitro to cytokines or from MLDS-treated mice displayed significantly increased HGF and c-Met levels, suggesting a potential role for HGF/c-Met in β-cell survival against diabetogenic agents. Adult PancMet KO mice displayed normal glucose and β-cell homeostasis, indicating that pancreatic c-Met loss is not detrimental for β-cell growth and function under basal conditions. However, PancMet KO mice were more susceptible to MLDS-induced diabetes. They displayed higher blood glucose levels, marked hypoinsulinemia, and reduced β-cell mass compared with wild-type littermates. PancMet KO mice showed enhanced intraislet infiltration, islet nitric oxide (NO) and chemokine production, and β-cell apoptosis. c-Met-null β-cells were more sensitive to cytokine-induced cell death in vitro, an effect mediated by NF-κB activation and NO production. Conversely, HGF treatment decreased p65/NF-κB activation and fully protected mouse and, more important, human β-cells against cytokines. CONCLUSIONS: These results show that HGF/c-Met is critical for β-cell survival by attenuating NF-κB signaling and suggest that activation of the HGF/c-Met signaling pathway represents a novel strategy for enhancing β-cell protection.


  • Open Access

    Survey of the Human Pancreatic β-Cell G1/S Proteome Reveals a Potential Therapeutic Role for Cdk-6 and Cyclin D1 in Enhancing Human β-Cell Replication and Function In Vivo

    by Nathalie Fiaschi-Taesch, Todd A. Bigatel, Brian Sicari, Karen K. Takane, Fatima Salim, Silvia Velazquez-Garcia, George Harb, Karen Selk, Irene Cozar-Castellano, Andrew F. Stewart

    OBJECTIVES: To comprehensively inventory the proteins that control the G1/S cell cycle checkpoint in the human islet and compare them with those in the murine islet, to determine whether these might therapeutically enhance human β-cell replication, to determine whether human β-cell replication can be demonstrated in an in vivo model, and to enhance human β-cell function in vivo. RESEARCH DESIGN AND METHODS: Thirty-four G1/S regulatory proteins were examined in human islets. Effects of adenoviruses expressing cdk-6, cdk-4, and cyclin D1 on proliferation in human β-cells were studied in both invitro and in vivo models. RESULTS: Multiple differences between murine and human islets occur, most strikingly the presence of cdk-6 in human β-cells versus its low abundance in the murine islet. Cdk-6 and cyclin D1 in vitro led to marked activation of retinoblastoma protein phosphorylation and cell cycle progression with no induction of cell death. Human islets transduced with cdk-6 and cyclin D1 were transplanted into diabetic NOD-SCID mice and markedly outperformed native human islets in vivo, maintaining glucose control for the entire 6 weeks of the study. CONCLUSIONS: The human G1/S proteome is described for the first time. Human islets are unlike their rodent counterparts in that they contain easily measurable cdk-6. Cdk-6 overexpression, alone or in combination with cyclin D1, strikingly stimulates human β-cell replication, both in vitro as well as in vivo, without inducing cell death or loss of function. Using this model, human β-cell replication can be induced and studied in vivo.